- Home
- APVO vs PTIX Comparison
APVO vs PTIX Comparison
Compare APVO & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- PTIX
- Stock Information
- Founded
- APVO 2016
- PTIX 1994
- Country
- APVO United States
- PTIX United States
- Employees
- APVO N/A
- PTIX N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- PTIX Health Care
- Exchange
- APVO Nasdaq
- PTIX Nasdaq
- Market Cap
- APVO 4.4M
- PTIX 3.7M
- IPO Year
- APVO N/A
- PTIX 2016
- Fundamental
- Price
- APVO $4.50
- PTIX $0.66
- Analyst Decision
- APVO Strong Buy
- PTIX
- Analyst Count
- APVO 1
- PTIX 0
- Target Price
- APVO $296.00
- PTIX N/A
- AVG Volume (30 Days)
- APVO 485.4K
- PTIX 258.9K
- Earning Date
- APVO 11-07-2024
- PTIX 11-14-2024
- Dividend Yield
- APVO N/A
- PTIX N/A
- EPS Growth
- APVO N/A
- PTIX N/A
- EPS
- APVO N/A
- PTIX N/A
- Revenue
- APVO N/A
- PTIX N/A
- Revenue This Year
- APVO N/A
- PTIX N/A
- Revenue Next Year
- APVO N/A
- PTIX N/A
- P/E Ratio
- APVO N/A
- PTIX N/A
- Revenue Growth
- APVO N/A
- PTIX N/A
- 52 Week Low
- APVO $3.65
- PTIX $0.45
- 52 Week High
- APVO $399.60
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- APVO 35.34
- PTIX 55.96
- Support Level
- APVO $3.65
- PTIX $0.50
- Resistance Level
- APVO $4.78
- PTIX $0.56
- Average True Range (ATR)
- APVO 1.95
- PTIX 0.06
- MACD
- APVO -0.70
- PTIX 0.01
- Stochastic Oscillator
- APVO 7.55
- PTIX 84.31
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.